34 related articles for article (PubMed ID: 26683631)
1. Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy.
Chester C; Fritsch K; Kohrt HE
Front Immunol; 2015; 6():601. PubMed ID: 26697006
[TBL] [Abstract][Full Text] [Related]
2. T-cell help in the tumor microenvironment enhances rituximab-mediated NK-cell ADCC.
Arora J; Ayyappan S; Yin C; Smith BJ; Lemke-Miltner CD; Wang Z; Farooq U; Weiner GJ
Blood; 2024 May; 143(18):1816-1824. PubMed ID: 38457360
[TBL] [Abstract][Full Text] [Related]
3. Enhancing CDC and ADCC of CD19 Antibodies by Combining Fc Protein-Engineering with Fc Glyco-Engineering.
Roßkopf S; Eichholz KM; Winterberg D; Diemer KJ; Lutz S; Münnich IA; Klausz K; Rösner T; Valerius T; Schewe DM; Humpe A; Gramatzki M; Peipp M; Kellner C
Antibodies (Basel); 2020 Nov; 9(4):. PubMed ID: 33212776
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphism of the inhibitory IgG Fc receptor FcgammaRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab.
Weng WK; Levy R
Leuk Lymphoma; 2009 May; 50(5):723-7. PubMed ID: 19452316
[TBL] [Abstract][Full Text] [Related]
5. Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies.
Lejeune J; Thibault G; Ternant D; Cartron G; Watier H; Ohresser M
J Clin Oncol; 2008 Nov; 26(33):5489-91; author reply 5491-2. PubMed ID: 18955438
[No Abstract] [Full Text] [Related]
6. Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment.
Cartron G; Ohresser M; Salles G; Solal-Céligny P; Colombat P; Watier H
Ann Oncol; 2008 Aug; 19(8):1485-1487. PubMed ID: 18408222
[TBL] [Abstract][Full Text] [Related]
7. Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy.
Hatjiharissi E; Hansen M; Santos DD; Xu L; Leleu X; Dimmock EW; Ho AW; Hunter ZR; Branagan AR; Patterson CJ; Kortsaris A; Verselis S; Fox E; Treon SP
Clin Lymphoma Myeloma; 2007 Jan; 7(4):286-90. PubMed ID: 17324336
[TBL] [Abstract][Full Text] [Related]
8. Correlation of FcγRIIIa Polymorphisms to the Response of Rituximab in Thai Patients with Diffuse Large B-Cell Lymphoma.
Angsirisak N; Wittayalertpanya S; Limpanasithikul W; Bunworasate U; Owattanapanich D
J Med Assoc Thai; 2015 Dec; 98(12):1215-21. PubMed ID: 27004307
[TBL] [Abstract][Full Text] [Related]
9. Scientific Significance of Clinically Insignificant FcγRIIIa-V158F Polymorphism.
Cartron G; Houot R; Kohrt HE
Clin Cancer Res; 2016 Feb; 22(4):787-9. PubMed ID: 26683631
[TBL] [Abstract][Full Text] [Related]
10. Rituximab by subcutaneous route.
Solal-Celigny P
Expert Rev Hematol; 2015 Apr; 8(2):147-53. PubMed ID: 25749209
[TBL] [Abstract][Full Text] [Related]
11. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.
Vidal L; Gafter-Gvili A; Leibovici L; Dreyling M; Ghielmini M; Hsu Schmitz SF; Cohen A; Shpilberg O
J Natl Cancer Inst; 2009 Feb; 101(4):248-55. PubMed ID: 19211444
[TBL] [Abstract][Full Text] [Related]
12. Rituximab as first-line maintenance therapy following rituximab-containing therapy for follicular lymphoma: profile report.
Croxtall JD
BioDrugs; 2011 Oct; 25(5):329-31. PubMed ID: 21942917
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]